Celiac Disease Market

The global Celiac Disease Market is valued at USD 600.2 Million in 2023 and is projected to reach a value of USD 1404.72 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 9.9% between 2024 and 2032. Rising incidence of celiac disease, particularly in developed regions, is fueling market growth as more individuals seek effective management solutions.

Key Highlights

• Celiac disease is an autoimmune disorder where the intake of gluten triggers an immune response that damages the lining of the small intestine. This damage hinders the proper absorption of nutrients from food, leading to various symptoms and potentially causing long-term health issues
• Based on the Treatment, Gluten Free Diet category accounted for significant market share of 39.5% in 2023
• In 2023, Oral route of administration dominated the market with largest market share of 59.8%
• North America dominated the market with 36.5% market share in 2023

Treatments Overview

​The Treatments segment is divided into Infliximab, Larazotide Acetate, Gluten-Free Diet, Others. The Gluten-Free Diet segment held the dominant share in 2023, accounting for significant market share of 39.5%.

The gluten-free diet remains the most common and primary treatment for managing celiac disease. It is considered the gold standard and the only medically recognized treatment for the condition. Strict adherence to a gluten-free diet is necessary to alleviate symptoms, promote intestinal healing, and prevent long-term complications associated with the disease. Although ongoing research is exploring alternative therapies, such as medications like Infliximab and Larazotide Acetate, these treatments have not yet become well-established or widely adopted in the market. These drugs aim to target specific aspects of the immune response triggered by gluten consumption.

Route of Administration Overview

The Route of Administration segment is divided into Oral and Parenteral. The Oral segment dominated the market with 59.8% market share in 2023.

The primary mode of delivery for celiac disease treatment is oral, largely because managing the condition revolves around strict adherence to a gluten-free diet, which involves avoiding gluten-containing foods and beverages. Oral administration pertains to the intake of food and medications by mouth, including gluten-free products as well as any prescribed drugs or supplements needed to manage the condition.

Regional Overview

In 2023, the North America captured 36.5% of the revenue share.

North America Celiac Disease market is driven by the a high rate of diagnosis due to greater awareness and advanced diagnostic tools, particularly in the United States. The region benefits from a well-established gluten-free food industry, which caters not only to those with celiac disease but also to health-conscious consumers. Additionally, substantial investment in research and development for novel treatments, as well as the presence of major pharmaceutical and biotech companies, fosters market growth. Supportive government regulations and initiatives aimed at improving diagnosis and treatment further contribute to the expansion of the celiac disease market in North America.

In Europe, celiac disease is notably prevalent in countries like Italy, Ireland, and Finland. European nations have implemented gluten-free labeling laws and standards, making gluten-free products more accessible. Increased awareness, higher diagnosis rates, and rising demand for gluten-free options in the food industry are key drivers of market growth in Europe.

Asia Pacific region is anticipated to grow at fastest rate during the forecast period driven by improved diagnosis rates, advancements in healthcare infrastructure, and a wider range of gluten-free product offerings. Awareness and diagnosis rates are lower in India, while countries like China, Japan, and Australia are experiencing a rise in urbanization, changing dietary habits, and increasing knowledge of celiac disease.

Based on the provided market data, Vantage Market Research offers customizations in the reports to meet the specific needs of clients.

Key Trends

• Rising Awareness and Diagnosis Rates: Improved diagnostic tools and growing public understanding are increasing the number of celiac disease diagnoses
• Development of Novel Pharmacological Therapies: Companies are focusing on treatments beyond gluten-free diets, including immunotherapies, enzyme therapies, and microbiome-modulating approaches
• Advancements in Clinical Trials: Pharmaceutical and biotech firms are actively progressing with clinical trials aimed at finding effective drug treatments for celiac disease
• Regulatory and Research Support: Increased regulatory backing and funding for celiac disease research are boosting innovation in the market

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Rising Prevalence of Celiac Disease Globally

The increasing incidence of celiac disease worldwide is a significant driver of market growth. More people are being diagnosed with celiac disease due to increased awareness and improved diagnostic skills. For instance, a study conducted by celiac Australia estimates that 360,000 Australians, or around one in every 70 persons, have celiac disease; of those who do, four out of five are not aware they have it. As healthcare systems evolve and understanding of the disease improves, the number of individuals seeking treatment is expected to rise.

Limited Availability and High Cost of Gluten-Free Products

While the demand for gluten-free products has surged, the availability of these items can be limited in certain regions, particularly in developing countries. Additionally, gluten-free products often come with a higher price tag, making them less accessible to some consumers. This can hinder adherence to the necessary gluten-free diet for those diagnosed with celiac disease. The high cost and limited selection creates gap in the market, highlighting the need for manufacturers to expand their offerings and improve accessibility, which could lead to increased competition and innovation.

Competitive Landscape

The Celiac Disease market is characterized by a growing number of pharmaceutical companies and biotech firms focusing on developing innovative treatments, as there is currently no approved curative therapy aside from a strict gluten-free diet. Key players like Takeda, 9 Meters Biopharma, ImmunogenX, and Provention Bio are leading the race with pipeline drugs aiming to manage symptoms or induce immune tolerance to gluten.

The key players in the global Celiac Disease market include - Asia Pacific Amgen, Anokion SA, BioLineRx Ltd, ChemoCentryx, Inc, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmunogenX, LLC, Innovate Biopharmaceuticals, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. among others.

The global Celiac Disease market can be categorized as Treatment, Route of Administration, End-user, Distribution Channel and Region.